About The Author

Editorial & Columns

Reporting on Scope 3 Emissions: Learning from Global Pharmaceutical MNCs

August 21, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Different Routes and Same Destination: Indian Pharmaceutical & FMCG Companies in Wellness Segment

August 14, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Risk Management and Pharmaceutical Companies in India

August 6, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Voluntary Licensing in Pharmaceutical Industry: Impact on Market Access & Pricing

August 1, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Divestitures in Pharmaceutical Industry: Indian Experience

July 25, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Evaluation and Revival of Special Economic Zones in India

July 18, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Spin-off  by Pharmaceutical Companies in India: Improved Focus and Valuation

July 11, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Competitive Intelligence in Pharmaceutical Industry

July 6, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Valuation Premium: India-listed Subsidiaries of Pharma and Healthcare MNCs Outshine Parent firms

June 26, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

India and Group of Seven (G7): Connected through Pharmaceuticals

June 21, 2024 | Dr. Anil Kumar Angrish | No Comments |

More